Navigation Links
DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
Date:4/1/2008

EL SEGUNDO, Calif., April 1, 2008 /PRNewswire/ -- DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney failure and disease, today announced its former Chief Medical Officer (CMO) Charles J. McAllister, M.D. will retire effective April 1, 2008. Dr. McAllister stepped down as CMO in July 2007, and has since served as CMO emeritus in the Office of the CMO.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

"Charlie has provided 30 years of incredible service to kidney care patients and the broader kidney care community, as a practicing nephrologist, as a hospital chief of staff and as DaVita's chief medical officer," said DaVita CEO Kent Thiry. "The combination of his energy, his intellect, his sense of humor and his warm bedside manner is amazing."

Dr. McAllister served as CMO for DaVita(R) since 2000. During that time, his dedication to continuous improvement in the areas of physician performance management, national clinical measurement development, product evaluation and testing, and clinical compliance program implementation, among others, helped DaVita become a national leader in clinical outcomes. Dr. McAllister's efforts also helped shaped DaVita's community-like work environment, which has been broadly written about and is taught at many major business schools.

"Dr. McAllister really represents the life-force of the Physician Council at DaVita, serving as DaVita's physician beacon of outstanding and compassionate care for our most vulnerable patients," said John Robertson, M.D. "All of the physicians remaining with the Office of the Chief Medical Officer will continue to aspire to the same level of professionalism and integrity that Charlie single handedly inspired since the day he joined with DaVita."

Prior to serving as CMO for DaVita, Dr. McAllister served as vice president of medical affairs for Gambro and Vivra, respectively. He also spent more than 20 years as medical director of dialysis facilities in the Tampa Bay area, where as one of the first practicing local nephrologists, he created dialysis programs serving a community of more than one million people.

"Of my major accomplishments, I'm especially proud of being given the honor to work with many colleagues, nurses, dieticians and others -- I was able to learn from them all," said Dr. McAllister. "As I retire from my executive career, I plan on working in the not-for-profit sector with the disadvantaged and underserved. I'm actually looking forward to putting back on my white coat and stethoscope."

Dr. McAllister has accepted a part-time position as medical director with Bay Area Treatment Center in Pinellas Park, Fla., where he will work with individuals suffering from substance dependence.

The Office of the CMO replaced the position of DaVita CMO on July 1, 2007. Membership comprises John Robertson, M.D., David Van Wyck, M.D. and Robert Provenzano, M.D.; and Allen Nissenson, M.D. serves as Special Advisor to the Office of the CMO.

DaVita is a registered trademark of DaVita Inc. All other trademarks are the property of their respective owners.

About DaVita Inc.

DaVita Inc., a FORTUNE 500(R) company, is a leading provider of kidney care in the United States, providing dialysis services and education for patients with chronic kidney failure and end stage renal disease. DaVita manages over 1,300 outpatient facilities and acute units in over 700 hospitals located in 43 states and the District of Columbia, serving approximately 107,000 patients. For more information, please visit http://www.davita.com.


'/>"/>
SOURCE DaVita Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NxStage Medical Announces Needle Supply Agreement with DaVita
2. DaVita to Present at UBS Best of Americas Conference
3. Human Pheromone Sciences Announces Quarterly and Full Year Results
4. Dragon Pharma announces 2007 full year financial results
5. Genaera Corporation Announces 2007 Financial Results
6. Genmab Announces Year End 2007 Financial Results
7. Immunosyn Corporation Announces 2007 Results, Files 10KSB
8. Elbit Imaging Ltd. Announces Results For Fiscal Year 2007
9. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
10. China Pharma Holdings, Inc. Announces Record 2007 Year End Results
11. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... August 15, 2017 , ... JULABO USA introduces its ... new website makes it easy to navigate through the site whether you’re in ... detailed product information, educational industry content and visit the company’s social media accounts, ...
(Date:8/11/2017)... ... August 11, 2017 , ... A staple in the ... month that will incorporate important key elements including a new digital marketing strategy and ... has supported them, Bill Miller has partnered with the South Texas Blood & Tissue ...
(Date:8/10/2017)... (PRWEB) , ... August 09, 2017 , ... ... regenerative medicine applications in the clinic is here. The team at Capricor Therapeutics, ... in conditioned medium for clinical studies. , Dr. Travis Antes, head of ...
(Date:8/10/2017)... ... August 10, 2017 , ... SPIE, ... Company Ltd. as its exclusive sales representative for SPIE Journals in Japan. Kinokuniya ... SPIE Digital Library in Japan. , “We look forward to expanding our relationship ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
Breaking Biology News(10 mins):